IR-Med

IR-Med EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of IR-Med (IRME) as of Oct 30, 2026 is -0.07. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.08 — a change of -12.06% (higher).

EV/FCF

-0.07

YoY

-12.06%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of IR-Med is 2024 -0.07 . EV/FCF (Enterprise Value to Free Cash Flow) of IR-Med was 2023 -0.08 . It decreases by -12.06% higher compared to the previous year.

The IR-Med EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-0.95 USD
Jan 1, 2020
-0.61 USD
Jan 1, 2021
-0.11 USD
Jan 1, 2022
-0.03 USD
Jan 1, 2023
-0.08 USD
Jan 1, 2024
-0.07 USD
The IR-Med EV/FCF history
YEAREV/FCFYoY
-0.07-12.06%
-0.08+181.01%
-0.03-73.96%
-0.11-82.05%
-0.61-35.66%
-0.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IR-Med Stock analysis

What does IR-Med do? IR-Med, Inc. develops non-invasive medical devices using Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company focuses on two principal products: PressureSafe, a handheld optical monitoring device for early detection of pressure injuries, and Nobiotics, an otoscope providing immediate indications for medical conditions. Healthcare professionals purchase these devices to detect biomarkers and molecules in real-time without invasive procedures. The company's initial product candidates are in various development stages, targeting medical indications requiring non-invasive diagnostics. IR-Med, Inc. generates revenue through the sale of PressureSafe and Nobiotics to healthcare providers. The devices are designed for specific medical applications, with PressureSafe addressing pressure injuries in bedridden patients and Nobiotics supporting physicians in otoscopic examinations. The company's business model centers on developing and commercializing these AI-enhanced medical devices to meet unmet diagnostic needs in healthcare settings. The firm's products are developed for real-time detection of biomarkers in blood and tissue, eliminating the need for invasive procedures. PressureSafe targets healthcare professionals managing bedridden patients, while Nobiotics serves physicians requiring immediate diagnostic insights during examinations. IR-Med, Inc. monetizes its technology through direct sales of these specialized medical devices to healthcare institutions and practitioners. IR-Med is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IR-Med stock

EV/FCF (Enterprise Value to Free Cash Flow) of IR-Med is -0.07 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of IR-Med changed from -0.08 to -0.07, representing a -12.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) IR-Med since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s IR-Med with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IR-Med

All Key Metrics — IR-Med